Source 1primary paper2025MED
Toolkit/donor antigen-reactive Tregs
donor antigen-reactive Tregs
Also known as: darTregs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Usefulness & Problems
Why this is useful
Donor antigen-reactive Tregs are described as a Treg-based therapy under study for transplantation. They represent a more antigen-focused branch of Treg therapy than polyclonal Tregs.; antigen-reactive Treg therapy in solid organ transplantation; reducing conventional systemic immunosuppression; preventing graft rejection
Source:
Donor antigen-reactive Tregs are described as a Treg-based therapy under study for transplantation. They represent a more antigen-focused branch of Treg therapy than polyclonal Tregs.
Source:
antigen-reactive Treg therapy in solid organ transplantation
Source:
reducing conventional systemic immunosuppression
Source:
preventing graft rejection
Problem solved
The approach is positioned to support graft tolerance while reducing reliance on conventional immunosuppression.; need for more targeted immune tolerance strategies in transplantation
Source:
The approach is positioned to support graft tolerance while reducing reliance on conventional immunosuppression.
Source:
need for more targeted immune tolerance strategies in transplantation
Problem links
need for more targeted immune tolerance strategies in transplantation
LiteratureThe approach is positioned to support graft tolerance while reducing reliance on conventional immunosuppression.
Source:
The approach is positioned to support graft tolerance while reducing reliance on conventional immunosuppression.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antigen-specific immune regulationTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
The abstract does not provide protocol details, but presents darTregs as a specialized Treg therapy format for transplant use.
The abstract states that antigen specificity still needs improvement and that dosing, manufacturing, and long-term safety remain open issues.; further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Virus-specific T cell therapies targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
VSTs targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
Clinical trials demonstrated the safety and feasibility of ex vivo-expanded Tregs in kidney and liver transplantation.
Clinical trials demonstrated the safety and feasibility of ex vivo-expanded Tregs in kidney and liver transplantation
Ex vivo-expanded Tregs in kidney and liver transplantation were associated with reduced rejection rates and lower infection risks.
supporting reduced rejection rates and lower infection risks
Further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns for cellular therapies in transplantation.
To establish their role in clinical transplantation, further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns.
Third-party off-the-shelf and multivirus-specific T cells allow faster availability and standardized scalable manufacturing compared to conventional virus-specific T cells.
Advances in third-party, "off-the-shelf" and multi-VSTs allow faster availability and standardized, scalable manufacturing compared to conventional VSTs.
Treg-based therapies including polyclonal Tregs, donor antigen-reactive Tregs, and CAR-Tregs are being studied to minimize conventional systemic immunosuppression while preventing graft rejection.
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug donor-antigen-reactive-tregs
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Source:
field limitationsupports
Further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns for cellular therapies in transplantation.
To establish their role in clinical transplantation, further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns.
Source:
therapeutic rationalesupports
Treg-based therapies including polyclonal Tregs, donor antigen-reactive Tregs, and CAR-Tregs are being studied to minimize conventional systemic immunosuppression while preventing graft rejection.
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Source:
Comparisons
Source-stated alternatives
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Source-backed strengths
explicitly framed as an antigen-reactive Treg approach
Source:
explicitly framed as an antigen-reactive Treg approach
Compared with CAR-T
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with CAR-T cells
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with CAR-Tregs
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with CAR-T therapy
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with chimeric antigen receptor T cells
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with Chimeric antigen receptor T-cell therapy
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with polyclonal Tregs
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Compared with virus-specific T cell therapies
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly framed as an antigen-reactive Treg approach.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source contrasts darTregs with polyclonal Tregs, CAR-Tregs, and virus-specific T cell therapies.
Ranked Citations
- 1.